79 related articles for article (PubMed ID: 2381746)
1. [The preclinical assessment of the activity and pharmacological action of native human interleukin-2].
Malakhova NV; Treshchalin ID; Iobadze MS; Abronina IF; Bykovskaia SN; Iushkov SF; Pereverzeva ER; Syrkin AB; Raushenbakh MO
Patol Fiziol Eksp Ter; 1990; (2):32-4. PubMed ID: 2381746
[TBL] [Abstract][Full Text] [Related]
2. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
Chao TY; Ohnishi H; Chu TM
Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
9. [The effect of various human interleukin-2 preparations and lymphokine-activated killer cells on antibody production in mice in vivo and human immunoglobulins in vitro].
Potapnev MP; Garbuzenko TS; Vozniuk AV; Ruksha EV; Shadrin OV; Bykovskaia SN
Biull Eksp Biol Med; 1994 Aug; 118(8):171-3. PubMed ID: 7949042
[No Abstract] [Full Text] [Related]
10. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
12. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
13. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
16. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes.
Ye W; Young JD; Liu CC
Cell Immunol; 1996 Nov; 174(1):54-62. PubMed ID: 8929454
[TBL] [Abstract][Full Text] [Related]
18. Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes.
Ratner S; Heppner GH
Cancer Res; 1988 Jun; 48(12):3374-80. PubMed ID: 2453269
[TBL] [Abstract][Full Text] [Related]
19. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
20. Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters.
Karapidaki I; Bakopoulou A; Papageorgiou A; Iakovidou Z; Mioglou E; Nikolaropoulos S; Mourelatos D; Lialiaris T
Mutat Res; 2009 Apr; 675(1-2):51-9. PubMed ID: 19386248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
